VRDN Insider Transactions
| Transaction Date (SEC Report ) |
Reporting Name | Relationship | Shrs. Owned | Type | Acq./Disp. | Shrs. Transacted | Price() | Amount() |
|---|---|---|---|---|---|---|---|---|
| 2023-03-13 | Myers Scott Dunseth | 255,500 | P-Purchase | A | 5,500 | 29.15 | 160,324.45 | |
| 2023-03-09 | Meisner Lara | officer: General Counsel and Secretary | 0 | S-Sale | D | 29,971 | 29.07 | 871,256.97 |
| 2023-02-08 | Katz Barrett | officer: Chief Medical Officer | 108,000 | A-Award | A | 108,000 | 34.20 | 3,693,600.00 |
| 2023-02-08 | Melvin Carrie | officer: COO | 54,000 | A-Award | A | 54,000 | 34.20 | 1,846,800.00 |
| 2023-02-08 | Humer Kristian | officer: CFO and CBO | 108,000 | A-Award | A | 108,000 | 34.20 | 3,693,600.00 |
| 2023-02-08 | Meisner Lara | officer: General Counsel and Secretary | 108,000 | A-Award | A | 108,000 | 34.20 | 3,693,600.00 |
| 2023-02-06 | Myers Scott Dunseth | director, officer: Chief Executive Officer | 250,000 | A-Award | A | 250,000 | 0.00 | 0.00 |
| 2023-02-06 | Myers Scott Dunseth | director, officer: Chief Executive Officer | 1,000,000 | A-Award | A | 1,000,000 | 35.80 | 35,800,000.00 |
| 2023-02-06 | Myers Scott Dunseth | director, officer: Chief Executive Officer | 0 | 0 | 0.00 | 0.00 | ||
| 2023-02-02 | Violin Jonathan | director, officer: Chief Executive Officer | 530,905 | M-Exempt | A | 50,000 | 0.15 | 7,500.00 |
| 2023-02-02 | Violin Jonathan | director, officer: Chief Executive Officer | 480,905 | S-Sale | D | 50,000 | 36.80 | 1,840,000.00 |
| 2023-02-02 | Violin Jonathan | director, officer: Chief Executive Officer | 239,205 | M-Exempt | D | 50,000 | 0.15 | 7,500.00 |
| 2023-02-02 | Violin Jonathan | director, officer: Chief Executive Officer | 430,905 | S-Sale | D | 50,000 | 36.80 | 1,840,000.00 |
| 2023-01-23 | Meisner Lara | officer: General Counsel and Secretary | 4,971 | M-Exempt | A | 4,971 | 23.03 | 114,482.13 |
| 2023-01-23 | Meisner Lara | officer: General Counsel and Secretary | 6,843 | M-Exempt | A | 1,872 | 14.00 | 26,208.00 |
| 2023-01-23 | Meisner Lara | officer: General Counsel and Secretary | 0 | S-Sale | D | 6,843 | 35.66 | 244,021.38 |
| 2023-01-23 | Meisner Lara | officer: General Counsel and Secretary | 39,750 | M-Exempt | D | 4,971 | 0.00 | 0.00 |
| 2023-01-23 | Meisner Lara | officer: General Counsel and Secretary | 20,003 | M-Exempt | D | 1,872 | 0.00 | 0.00 |
| 2023-01-13 | Katz Barrett | officer: Chief Medical Officer | 4,147 | M-Exempt | A | 4,147 | 23.03 | 95,505.41 |
| 2023-01-17 | Katz Barrett | officer: Chief Medical Officer | 24,853 | M-Exempt | A | 24,853 | 23.03 | 572,364.59 |
| 2023-01-17 | Katz Barrett | officer: Chief Medical Officer | 0 | S-Sale | D | 24,853 | 37.21 | 924,780.13 |
| 2023-01-13 | Katz Barrett | officer: Chief Medical Officer | 291,853 | M-Exempt | D | 4,147 | 0.00 | 0.00 |
| 2023-01-17 | Katz Barrett | officer: Chief Medical Officer | 267,000 | M-Exempt | D | 24,853 | 0.00 | 0.00 |
| 2023-01-09 | Katz Barrett | officer: Chief Medical Officer | 12,623 | M-Exempt | A | 12,623 | 23.03 | 290,707.69 |
| 2023-01-10 | Katz Barrett | officer: Chief Medical Officer | 47,377 | M-Exempt | A | 47,377 | 23.03 | 1,091,092.31 |
| 2023-01-10 | Katz Barrett | officer: Chief Medical Officer | 0 | S-Sale | D | 47,377 | 35.30 | 1,672,408.10 |
| 2023-01-09 | Katz Barrett | officer: Chief Medical Officer | 343,377 | M-Exempt | D | 12,623 | 0.00 | 0.00 |
| 2023-01-10 | Katz Barrett | officer: Chief Medical Officer | 296,000 | M-Exempt | D | 47,377 | 0.00 | 0.00 |
| 2022-12-20 | Meisner Lara | officer: General Counsel and Secretary | 600 | M-Exempt | A | 600 | 23.03 | 13,818.00 |
| 2022-12-21 | Meisner Lara | officer: General Counsel and Secretary | 16,326 | M-Exempt | A | 16,326 | 23.03 | 375,987.78 |
| 2022-12-21 | Meisner Lara | officer: General Counsel and Secretary | 0 | S-Sale | D | 16,326 | 29.19 | 476,555.94 |
| 2022-12-20 | Meisner Lara | officer: General Counsel and Secretary | 61,047 | M-Exempt | D | 600 | 0.00 | 0.00 |
| 2022-12-21 | Meisner Lara | officer: General Counsel and Secretary | 44,721 | M-Exempt | D | 16,326 | 0.00 | 0.00 |
| 2022-12-15 | Meisner Lara | officer: General Counsel and Secretary | 300 | M-Exempt | A | 300 | 23.03 | 6,909.00 |
| 2022-12-16 | Meisner Lara | officer: General Counsel and Secretary | 1,297 | M-Exempt | A | 1,297 | 23.03 | 29,869.91 |
| 2022-12-16 | Meisner Lara | officer: General Counsel and Secretary | 0 | S-Sale | D | 1,297 | 28.44 | 36,886.68 |
| 2022-12-15 | Meisner Lara | officer: General Counsel and Secretary | 62,944 | M-Exempt | D | 300 | 0.00 | 0.00 |
| 2022-12-16 | Meisner Lara | officer: General Counsel and Secretary | 61,647 | M-Exempt | D | 1,297 | 0.00 | 0.00 |
| 2022-12-12 | Meisner Lara | officer: General Counsel and Secretary | 600 | M-Exempt | A | 600 | 23.03 | 13,818.00 |
| 2022-12-14 | Meisner Lara | officer: General Counsel and Secretary | 15,656 | M-Exempt | A | 15,656 | 23.03 | 360,557.68 |
| 2022-12-14 | Meisner Lara | officer: General Counsel and Secretary | 0 | S-Sale | D | 15,656 | 28.12 | 440,246.72 |
| 2022-12-12 | Meisner Lara | officer: General Counsel and Secretary | 78,900 | M-Exempt | D | 600 | 0.00 | 0.00 |
| 2022-12-14 | Meisner Lara | officer: General Counsel and Secretary | 63,244 | M-Exempt | D | 15,656 | 0.00 | 0.00 |
| 2022-11-15 | Meisner Lara | officer: General Counsel and Secretary | 8,125 | M-Exempt | A | 8,125 | 14.00 | 113,750.00 |
| 2022-11-15 | Meisner Lara | officer: General Counsel and Secretary | 0 | S-Sale | D | 8,125 | 22.05 | 179,156.25 |
| 2022-11-15 | Meisner Lara | officer: General Counsel and Secretary | 21,875 | M-Exempt | D | 8,125 | 0.00 | 0.00 |
| 2022-08-17 | Fairmount Healthcare Fund II L.P. | director: | 1,363,764 | P-Purchase | A | 425,531 | 23.50 | 9,999,978.50 |
| 2022-06-21 | Melvin Carrie | officer: COO | 0 | D | 210,000 | 10.63 | 2,232,300.00 | |
| 2022-06-08 | Moses Jennifer K. | director: | 12,500 | A-Award | A | 12,500 | 0.00 | 0.00 |
| 2022-06-08 | Kiselak Tomas | director: | 12,500 | A-Award | A | 12,500 | 0.00 | 0.00 |
| 2022-06-08 | Harwin Peter Evan | director: | 12,500 | A-Award | A | 12,500 | 0.00 | 0.00 |
| 2022-06-08 | Morris Arlene | director: | 12,500 | A-Award | A | 12,500 | 0.00 | 0.00 |
| 2022-06-01 | Violin Jonathan | officer: Chief Executive Officer | 480,905 | S-Sale | D | 30,000 | 12.20 | 366,000.00 |
| 2022-05-02 | Violin Jonathan | officer: Chief Executive Officer | 510,905 | S-Sale | D | 30,000 | 13.04 | 391,200.00 |
| 2022-04-01 | Violin Jonathan | officer: Chief Executive Officer | 540,905 | S-Sale | D | 3,600 | 18.93 | 68,148.00 |
| 2022-03-01 | Violin Jonathan | director, officer: Chief Executive Officer | 582,011 | S-Sale | D | 18,894 | 17.82 | 336,691.08 |
| 2022-03-02 | Violin Jonathan | director, officer: Chief Executive Officer | 570,905 | S-Sale | D | 11,106 | 17.36 | 192,800.16 |
| 2022-02-02 | Humer Kristian | officer: CFO and CBO | 90,000 | A-Award | A | 90,000 | 18.51 | 1,665,900.00 |
| 2022-02-02 | Katz Barrett | officer: Chief Medical Officer | 110,000 | A-Award | A | 110,000 | 18.51 | 2,036,100.00 |
| 2022-02-02 | Meisner Lara | officer: General Counsel and Secretary | 90,000 | A-Award | A | 90,000 | 18.51 | 1,665,900.00 |
| 2022-02-01 | Violin Jonathan | director, officer: Chief Executive Officer | 614,154 | S-Sale | D | 16,751 | 19.55 | 327,482.05 |
| 2022-02-02 | Violin Jonathan | director, officer: Chief Executive Officer | 601,814 | S-Sale | D | 12,340 | 18.47 | 227,919.80 |
| 2022-02-03 | Violin Jonathan | director, officer: Chief Executive Officer | 600,905 | S-Sale | D | 909 | 19.16 | 17,416.44 |
| 2022-02-02 | Violin Jonathan | director, officer: Chief Executive Officer | 280,000 | A-Award | A | 280,000 | 18.51 | 5,182,800.00 |
| 2021-12-31 | Humer Kristian | officer: CFO and CBO | 121,371 | A-Award | A | 121,371 | 19.77 | 2,399,504.67 |
| 2021-12-08 | Violin Jonathan | director, officer: See Remarks | 630,905 | C-Conversion | A | 627,564 | 0.00 | 0.00 |
| 2021-12-08 | Violin Jonathan | director, officer: See Remarks | 0 | C-Conversion | D | 9,413 | 0.00 | 0.00 |
| 2021-10-01 | Meisner Lara | officer: General Counsel and Secretary | 0 | D | 79,500 | 23.03 | 1,830,885.00 | |
| 2021-10-01 | Meisner Lara | officer: General Counsel and Secretary | 0 | D | 30,000 | 14.00 | 420,000.00 | |
| 2021-09-23 | Frazier Life Sciences Public Fund, L.P. | 10 percent owner | 1,505,200 | P-Purchase | A | 200,000 | 11.00 | 2,200,000.00 |
| 2021-09-21 | Fairmount Funds Management LLC | director, 10 percent owner: | 938,233 | P-Purchase | A | 909,000 | 11.00 | 9,999,000.00 |
| 2021-08-16 | Frazier Life Sciences Public Fund, L.P. | 10 percent owner | 1,305,200 | D | 0 | 0.00 | 0.00 | |
| 2021-07-26 | Humer Kristian | officer: CFO and CBO | 360,000 | A-Award | A | 360,000 | 17.09 | 6,152,400.00 |
| 2021-07-26 | Humer Kristian | officer | 0 | 0 | 0.00 | 0.00 | ||
| 2021-07-26 | Humer Kristian | officer | 0 | 0 | 0.00 | 0.00 | ||
| 2021-07-14 | Moses Jennifer K. | director | 25,000 | A-Award | A | 25,000 | 17.88 | 447,000.00 |
| 2021-07-14 | Moses Jennifer K. | director: | 0 | 0 | 0.00 | 0.00 | ||
| 2021-06-03 | Kiselak Tomas | director | 12,500 | A-Award | A | 12,500 | 16.60 | 207,500.00 |
| 2021-06-03 | Morris Arlene | director | 12,500 | A-Award | A | 12,500 | 16.60 | 207,500.00 |
| 2021-06-03 | Harwin Peter Evan | director | 12,500 | A-Award | A | 12,500 | 16.60 | 207,500.00 |
| 2021-02-04 | TURNER JOSEPH L | director | 25,000 | A-Award | A | 25,000 | 20.50 | 512,500.00 |
| 2021-02-04 | Hatfield Jeffrey S. | director | 25,000 | A-Award | A | 25,000 | 20.50 | 512,500.00 |
| 2021-02-04 | Harwin Peter Evan | director | 25,000 | A-Award | A | 25,000 | 20.50 | 512,500.00 |
| 2021-02-04 | Kiselak Tomas | director | 25,000 | A-Award | A | 25,000 | 20.50 | 512,500.00 |
| 2021-02-04 | Morris Arlene | director | 25,000 | A-Award | A | 25,000 | 20.50 | 512,500.00 |
| 2021-01-20 | Katz Barrett | officer | 0 | 0 | 0.00 | 0.00 | ||
| 2021-01-18 | Katz Barrett | officer: Chief Medical Officer | 356,000 | A-Award | A | 356,000 | 23.03 | 8,198,680.00 |
| 2021-01-18 | Leverone Jason A. | officer: Chief Financial Officer | 311,785 | A-Award | A | 311,785 | 23.03 | 7,180,408.55 |
| 2021-01-18 | Violin Jonathan | director, officer: CEO and President | 800,075 | A-Award | A | 800,075 | 23.03 | 18,425,727.25 |
| 2021-01-15 | Escolar Diana | officer | 0 | 0 | 0.00 | 0.00 | ||
| 2021-01-18 | Rauch Lee M. | 15,000 | A-Award | A | 15,000 | 23.03 | 345,450.00 | |
| 2020-10-15 | Marshall William Stuart | 0 | 0 | 0.00 | 0.00 | |||
| 2020-12-07 | RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 410,686 | I | 0 | 0.00 | 0.00 | |
| 2020-11-10 | Point72 Asset Management, L.P. | 10 percent owner | 426,162 | I | 0 | 0.00 | 0.00 | |
| 2020-11-09 | Logos Global Master Fund LP | 10 percent owner | 6,250,000 | P-Purchase | A | 250,000 | 1.10 | 274,475.00 |
| 2020-11-09 | Logos Global Master Fund LP | 10 percent owner | 6,350,000 | P-Purchase | A | 100,000 | 1.16 | 116,410.00 |
| 2020-11-13 | Logos Global Master Fund LP | 10 percent owner | 550,000 | P-Purchase | A | 126,667 | 14.84 | 1,879,598.95 |
| 2020-11-04 | Logos Global Master Fund LP | 10 percent owner | 6,000,000 | D | 0 | 0.00 | 0.00 | |
| 2020-10-27 | Violin Jonathan | officer: President and COO | 50,124 | J-Other | A | 50,124 | 0.00 | 0.00 |
| 2020-10-27 | Violin Jonathan | officer: President and COO | 4,338,079 | J-Other | A | 4,338,079 | 0.01 | 43,380.79 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Group doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Group or anyone involved with Discounting Cash Flows Group will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.